A REVIEW ON PI3K INHIBITORS IN OVARIAN CANCER

Ovarian cancer remains a major cause of gynaecologic cancer death, and the PI3K/AKT/mTOR pathway is often aberrant in its development. This review exhaustively reviews the therapeutic utility of PI3K inhibitors in ovarian cancer as pan-PI3K, isoform-selective, and dual PI3K/mTOR inhibitors. Despite their promising preclinical and clinical activity, these drugs are not as effective as they are when used alone due to limitations such as drug resistance, toxicity, and activation of compensatory pathways. To overcome these limitations, recent research has suggested that combining therapies that include PARP inhibitors, MEK/ERK inhibitors, chemotherapy, immune checkpoint inhibitors, and anti-angiogenic agents is necessary. The review focuses on the current evidence on PI3K-targeted therapies, their resistance mechanisms, and new combination regimens to date. It emphasizes the necessity of further clinical study to establish their place in improving the survival of ovarian cancer patients.